TMOD-36. SUCCESSFUL GENERATION OF FIVE PATIENT-DERIVED ENDOGENOUS IDH1 MUTANT GLIOMA CELL LINES PROVIDES OPPORTUNITIES FOR DEVELOPMENT OF NEW TREATMENT STRATEGIES FOR IDH MUTANT GLIOMAS